Appeal No. 94-1696
Application 07/811,129
1. A soluble fusion molecule comprising a first region, having
binding specificity for CD11a/CD18, operatively linked to a
second region substantially corresponding to an
immunoglobulin constant region.
2. The fusion molecule of claim 1, wherein the first region
substantially corresponds to an extracellular portion of
ICAM-2.
9. A method for activating T cells comprising contacting T
cells with a ligand capable of binding to CD3 on said T
cells and an effective costimulatory amount of a soluble
fusion molecule to activate the T cells, said soluble fusion
molecule comprising a first region, having binding
specificity for CD11a/CD18, operatively linked to a second
region substantially corresponding to an immunoglobulin
constant region.
The references relied on by the examiner are:
Springer, T.A. “Adhesion Receptors of the Immune System,” Nature,
vol. 346, pp. 425-434 (1990).
Staunton et al., (Staunton), “Functional Cloning of ICAM-2, a
Cell Adhesion Ligand for LFA-1 Homologous to ICAM-1,” Nature,
vol. 339, pp. 61-64 (1989).
Zettlmeissl, et al. (Zettlmeissl), “Expression and
Characterization of Human CD4: Immunoglobulin Fusion Proteins,”
DNA and Cell Biology, vol. 9, pp. 347-353 (1990).
The references relied on by this merits panel are:
Altmann et al. (Altmann), “Cotransfection of ICAM-1 and HLA-DR
Reconstitutes Human Antigen-Presenting Cell Function in Mouse L
Cells,” Nature, vol. 338, pp. 512-514 (1989).
Boyd et al. (Boyd), “Intercellular Adhesion 1 (ICAM-1) has a
Central Role in Cell-Cell Contact-Mediated Immune Mechanisms,”
Proc. Natl. Acad. Sci. USA, vol. 85, pp. 3095-3099 (1988).
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007